May 24, 2022

Medical Trend

Medical News and Medical Resources

A cheap antidepressant can reduce risks of COVID-19 disease by about 1/3

A cheap antidepressant can reduce risks of COVID-19 disease by about 1/3



 

Research shows: A cheap antidepressant can reduce risks of COVID-19 disease by about 1/3.

 

According to a report on the CNN website on the 28th, a study published in the journal The Lancet Global Health on Wednesday showed that a cheap, universal antidepressant can reduce the risk of severe COVID-19 disease in high-risk groups by nearly a third one.

 

Fluvoxamine is commonly used clinically to treat mental illnesses such as depression and obsessive-compulsive disorder. Because it contains anti-inflammatory ingredients, it was selected for COVID-19 treatment trials.

 

Researchers studied 1,500 COVID-19 outpatients in Brazil and found that among the 741 people who received fluvoxamine treatment, 79 were hospitalized, accounting for about 11%; among the 756 people who used placebo, 119 were hospitalized, about 11%. Accounted for 15.7%. 

The study also found that 12 of the placebo patients died, while only 1 of the fluvoxamine patients died. The absolute risk was reduced by 5% and the relative risk was reduced by 32%.

 

Dr. Angela Ryerson, associate professor of psychiatry at Washington University in St. Louis, also participated in the study.

 

“Fluvoxamine may reduce the production of inflammatory molecules called cytokines caused by SARS-CoV-2 infection.” Ryerson said in a statement that the drug will also reduce blood clots caused by coronavirus infections.

 

In addition to effectiveness, the price of fluvoxamine is also quite cheap. The price of a course of treatment for 10 days is only US$4, which is far lower than the US$2,000 of monoclonal antibody “cocktail therapy” and US$700 of Merck’s monabivir.

 

However, what dose of fluvoxamine should be used to treat the COVID-19, whether low-risk patients will benefit, and whether the drug needs to be used in conjunction with other drugs is still doubtful. Moreover, because fluvoxamine is not included in the WHO’s list of essential drugs, there is also the possibility of addiction. The researchers emphasized that further research on the drug is necessary.

 

 

 

A cheap antidepressant can reduce risks of COVID-19 disease by about 1/3

(source:internet, reference only)


Disclaimer of medicaltrend.org